$1.97
+0.06 (+3.14%)
Open$1.96
Previous Close$1.91
Day High$2.05
Day Low$1.94
52W High$29.33
52W Low$12.16
Volume—
Avg Volume60.4K
Market Cap72.95M
P/E Ratio34.75
EPS$0.60
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,016.2% upside
Current
$1.97
$1.97
Target
$21.99
$21.99
$18.66
$21.99 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 31.19M | 31.61M | 26.89M |
| Net Income | 2.24M | 2.16M | 1.99M |
| Profit Margin | 7.2% | 6.8% | 7.4% |
| EBITDA | 3.54M | 3.42M | 2.98M |
| Free Cash Flow | 1.72M | 2.00M | 2.13M |
| Rev Growth | -3.9% | +21.8% | -6.2% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |